In this work we explored if an atlas-based comparison approach reveals shape differences in the prostate capsule as observed on pre-treatment T2-weighted MRI between prostate cancer patients who do (BCR+) and do not (BCR−) have BCR following definitive therapy. The gene discussed is BCR; the disease is prostate carcinoma.